PCN Insights, News, Videos, and More

Following his insightful session at Psych Congress 2024, Snoben Kuruvila, MPAS, PA-C, sat down with Psych Congress Network to discuss emerging developments in major depressive disorder (MDD) treatment.

A systematic review found no evidence of a beneficial effect from beta-blockers in treating anxiety symptoms in patients with social phobia or panic disorder with or without agoraphobia compared to either placebo or benzodiazepines.

Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.

Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.

A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.

A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.

Join Rakesh Jain, MD, MPH, as he explores the role of viloxazine extended-release (ER) in targeting hyperactivity and impulsivity in adolescents with ADHD.

A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 

In this video, Craig Chepke, MD, DFAPA, discusses effective communication strategies clinicians can use when introducing long-acting injectable (LAI) antipsychotics to patients for the treatment of schizophrenia.